Inhibiting the expression, or blocking the function, of VEGF-C/D to control peritumoral lymphangiogenesis is expected to lead to the development of novel therapeutic strategies for the treatment and management of breast cancer; however, further characterization of the molecular mechanisms which regulate lymphangiogenesis is still required. Here, VEGFC is linked to breast cancer.